Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett January 23, 2025 Ram W. Sabnis, Anika R. Sabnis 3 citations
No Summary
ACS Med Chem Lett
ISSN 1948-5875
6 papers in the library · 6 citations · publishing 2023-2026
Papers
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
ACS Med Chem Lett August 18, 2023 Robert B. Kargbo 3 citations
This viewpoint argues that combining biomarkers, psychedelics, and artificial intelligence could improve psychiatric diagnostics, prognosis, and treatment. Psychedelics show promise in therapy, and AI may help predict how individuals will respond to treatments. However, significant challenges remain, including ethical and practical hurdles. The authors call for further research to develop more precise, personalized psychiatric care.
Novel Indoline Derivatives Serotonergic Psychedelic Agents as 5‑HT2A Agonists for Treating Psychosis, Mental Illness and CNS Disorders.
ACS Med Chem Lett April 27, 2026 Ram W. Sabnis, Anika R. Sabnis
No Summary
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
ACS Med Chem Lett February 13, 2025 Ram W. Sabnis, Anika R. Sabnis
The text describes novel tryptamine compounds that act as agonists at the 5-HT2A receptor, a serotonin receptor subtype, for potential treatment of mood disorders including depressive disorders and bipolar disorders. The work presents these compounds as a therapeutic approach, but no specific findings, experimental results, or clinical data are reported.
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
ACS Med Chem Lett January 4, 2025 Ram W. Sabnis
The text describes a class of novel chemical compounds, 3-cycloaminoindoles, that act as serotonergic psychedelic agents. These compounds are proposed for potential therapeutic use in treating psychosis, mental illness, and other central nervous system (CNS) disorders. The abstract indicates the compounds are designed to interact with serotonin receptors, a common target for psychedelic and psychiatric drugs, but provides no experimental data, results, or evidence of efficacy.
Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.
ACS Med Chem Lett November 11, 2024 Robert B. Kargbo
Three new classes of psilocin-related compounds—4-pivaloyloxy-N-methyltryptammonium chloride, alkyl quaternary ammonium tryptamines, and 4-pivaloyloxy-N-methyltryptammonium derivatives—have been developed to improve stability, bioavailability, and efficacy for treating depression, anxiety, and substance use disorders. Preclinical studies indicate these innovations may overcome limitations of traditional psychedelics, offering more reliable therapeutic options for mental and neurological disorders.